At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 222 enrolled
Drug / intervention
solifenacin succinate +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate With 0.4 mg Tamsulosin Hydrochloride OCAS (TOCAS) Using Urodynamics in Male Subjects With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
In Brief
A Phase 2 clinical trial evaluating solifenacin succinate, tamsulosin hydrochloride, and 2 other interventions for Lower Urinary Tract Symptoms and Bladder Outlet Obstruction. Completed, enrolled 222 participants across 33 sites in 6 countries.
Detailed Summary
A study to evaluate the safety of the co-administration of solifenacin succinate with tamsulosin hydrochloride in men with lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Czechia, Germany, Hungary, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedJul 2007
Primary CompletionAug 2008
TodayJul 2026
First PostedJul 26, 2007
Enrollment StartJun 1, 2007
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.9 years ago
Interventions
solifenacin succinatedrug
Solifenacin succinate tablets
tamsulosin hydrochloridedrug
Tamsulosin hydrochloride Oral Control Absorption System (TOCAS) tablets
Placebo to solifenacindrug
Placebo to tamsulosindrug